Biogen struck an exclusive licensing deal with Vanqua Bio, paying $70 million up front for global rights to a preclinical C5aR1 antagonist that targets innate immune signaling. The agreement gives Biogen control of development, manufacturing and commercialization, with up to $990 million in downstream milestones and tiered royalties to Vanqua. Biogen framed the move as a deliberate expansion into immunology, citing C5aR1 as a well‑validated inflammatory target. The company said positive preclinical data support advancement toward first‑in‑human studies, with an eye on an IND path in the coming years.